Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07452471

Comparison of the Postoperative Analgesic Effects of the Temperature-responsive Gel Mixed With Local Anesthetics Application and Ultrasound-guided Transversus Abdominis Plane Block in Patients Undergoing Laparoscopic Gastrectomy

This study is a single-center, prospective, randomized controlled trial designed to compare two established postoperative analgesic strategies in adult patients undergoing laparoscopic gastrectomy under general anesthesia.

Effective pain control after laparoscopic gastrectomy is essential to promote early recovery, facilitate ambulation, reduce opioid consumption, and improve overall postoperative outcomes. Although minimally invasive techniques reduce surgical trauma, patients frequently experience moderate postoperative pain arising from abdominal wall incisions and trocar insertion sites.

This trial compares two analgesic approaches:

Ultrasound-guided bilateral transversus abdominis plane (TAP) block using 0.2% ropivacaine

Local application of a thermosensitive ropivacaine-poloxamer 407 hydrogel formulation (Welpass®) applied to the surgical site at the end of surgery

A total of 80 patients (age ≥19 years, American Society of Anesthesiologists physical status I-III) scheduled for elective laparoscopic gastrectomy will be enrolled at a single institution. Participants will be randomly assigned in a 1:1 ratio to either the TAP block group (n=40) or the hydrogel group (n=40).

In the TAP block group, 0.2% ropivacaine will be injected bilaterally between the internal oblique and transversus abdominis muscles under ultrasound guidance at the completion of surgery.

In the hydrogel group, a mixture of ropivacaine and poloxamer 407-based gel (Welpass®) will be prepared and applied locally to the surgical site, including the fascial plane and subcutaneous tissue, prior to wound closure.

All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) according to institutional protocols.

The primary objective of the study is to compare postoperative pain intensity between the two groups. Pain will be assessed using the Visual Analog Scale (VAS) immediately upon arrival in the post-anesthesia care unit (PACU), just before PACU discharge, and at 12 and 24 hours after surgery.

Secondary outcomes include:

* Total PCA consumption within 48 hours * Additional analgesic use (total dose and frequency) * Time to first flatus * Time to ambulation * Length of hospital stay * Incidence of postoperative nausea and vomiting (PONV)

Safety will be evaluated by monitoring adverse events, including signs of local anesthetic systemic toxicity or other serious complications. Both analgesic techniques involve medications and procedures that are widely used in routine clinical practice. The study uses approved drugs within standard dosing ranges and is conducted by experienced clinicians. If a serious adverse event suspected to be related to the intervention occurs, appropriate medical management will be provided immediately, and the Institutional Review Board (IRB) will be notified in accordance with regulatory requirements.

Participants may be withdrawn from the study if they experience a serious adverse reaction related to the intervention, if conversion to open surgery occurs, or if they choose to withdraw consent.

The aim of this study is to determine whether local application of sustained-release ropivacaine hydrogel provides analgesic efficacy comparable or superior to ultrasound-guided TAP block. The findings may help identify an effective and safe postoperative pain management strategy for patients undergoing laparoscopic gastrectomy and contribute to optimizing multimodal analgesia protocols in minimally invasive gastric surgery.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Yangsan Pusan National University Hospital

Yangsan, Gyeongsamnamdo, 50612, South Korea

Location contact

Gyeongjo Byun, MD

CONTACT

[email protected]

82-10-5663-1713

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 19 years or older undergoing laparoscopic gastrectomy under general anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III

Exclusion criteria

  • Known hypersensitivity or allergy to local anesthetics
  • Presence of autoimmune disease or dermatologic conditions such as keloids
  • Conversion from laparoscopic surgery to open surgery
  • Pregnant women
  • Chronic opioid use for persistent pain
  • Inability to communicate effectively, making pain assessment difficult
  • Refusal to participate in the study

Treatment and study plan

Ultrasound-guided Transversus Abdominis Plane (TAP) Block

Procedure

Bilateral ultrasound-guided injection of 0.2% ropivacaine between the internal oblique and transversus abdominis muscles at the end of surgery

Ropivacaine-Poloxamer 407 Hydrogel (Welpass®)

Drug

Local application of a thermosensitive hydrogel containing ropivacaine and poloxamer 407 to the fascial and subcutaneous layers at the surgical site prior to wound closure

Primary outcomes

  1. Postoperative Pain Intensity

    Time frame: postoperative period(immediately upon arrival in PACU, at PACU discharge, 12,24 hours after surgery)

    Postoperative pain intensity measured using the Visual Analog Scale (VAS, 0-10) immediately upon arrival in the post-anesthesia care unit (PACU) and just before PACU discharge. The VAS ranges from 0 (no pain) to 10 (worst imaginable pain). Mean pain scores will be compared between the two groups

Secondary outcomes

  1. Total Patient-Controlled Analgesia (PCA) Consumption

    Time frame: 48 hours postoperatively

    Total cumulative dose of intravenous patient-controlled analgesia administered during the first 48 hours after surgery.

  2. Total Rescue Analgesic Dose

    Time frame: 48 hours postoperatively

    Total cumulative dose of additional rescue analgesics administered within 48 hours after surgery.

  3. Number of Rescue Analgesic Administrations

    Time frame: 48 hours postoperatively

    Total number of additional rescue analgesic administrations within 48 hours after surgery.

  4. Number of PONV Episodes

    Time frame: 48 hours postoperatively

    Total number of postoperative nausea and vomiting episodes occurring within 48 hours after surgery.

  5. Time to First Flatus

    Time frame: From the end of surgery until the first documented passage of flatus, assessed up to 7 days postoperatively

    Time from the end of surgery to the first passage of flatus, measured in hours.

  6. Time to First Ambulation

    Time frame: From end of surgery to first ambulation, assessed up to 7 postoperative days

    Time from the end of surgery to first ambulation, measured in hours.

  7. Length of Postoperative Hospital Stay

    Time frame: From date of surgery to date of discharge, assessed up to 30 days postoperatively

    Duration of hospitalization from the date of surgery to the date of discharge, measured in days.

Study contacts

Contact information is provided by the study sponsor or research team.

Gyeong Jo Byun, MD

CONTACT

[email protected]

82-10-5663-1713

Sponsors and collaborators

Lead sponsor

Gyeong-Jo Byeon, MD, PhD

Other

Registry information

Acronym: TAP-WELPASS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 5, 2026
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.